13F Holdings
中文EN

IART INTEGRA LIFESCIENCES HOLDINGS CORP

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 917520 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.8%
TTM net income YoY102.6%
TTM EPS YoY102.6%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-49.5%

Margins

Gross margin52.4%
Operating margin4.4%
Net margin0.8%
FCF margin5.2%
EBITDA margin—

Returns

ROE1.2%
ROA0.4%
ROIC (approx.)2.8%
Asset turnover0.46x

Leverage & solvency

Liabilities / assets69.6%
Debt / equity0.65x
Current ratio3.62x
Interest coverage0.79x

Cash quality & payout

Operating cash flow / net income10.79x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue3.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.64B$1.61B$1.54B$1.56B$1.54B
Cost of revenue$803.62M$728.47M$656.84M$587.36M$597.81M
Gross profit$831.62M$882.06M$884.74M$970.31M$944.64M
R&D expense$98.97M$115.38M$104.19M$101.19M$93.05M
SG&A expense$699.70M$716.98M$656.64M$616.32M$637.45M
Operating income-$493.37M$28.41M$111.53M$238.92M$197.23M
Interest expense$86.25M$70.63M$51.38M$49.59M$50.40M
Pretax income-$563.50M-$18.24M$81.07M$213.89M$214.68M
Income tax-$47.03M-$11.29M$13.33M$33.34M$45.60M
Net income-$516.47M-$6.94M$67.74M$180.55M$169.07M
EBITDA-$448.57M$70.81M$152.43M$279.02M$236.63M
EPS (basic)-6.74-0.090.852.182.00
EPS (diluted)-6.74-0.090.842.161.98
Weighted avg. shares (diluted)76.67M77.01M80.34M83.52M85.48M
Balance sheet
Cash & equivalents$235.05M$246.38M$276.40M$456.66M$513.45M
Short-term investments$28.69M$27.19M$32.69M$0—
Receivables$278.85M$272.37M$259.33M$263.46M$231.83M
Inventory$492.74M$429.09M$389.61M$324.58M$317.39M
Current assets$1.16B$1.08B$1.06B$1.16B$1.15B
PP&E, net$444.33M$405.72M$340.20M$311.30M$311.70M
Goodwill$615.16M$1.10B$1.06B$1.04B$1.01B
Intangibles$1.13B$1.21B$1.07B$1.13B$1.15B
Total assets$3.60B$4.04B$3.78B$3.89B$3.78B
Current liabilities$455.98M$922.13M$306.98M$320.91M$340.02M
Long-term debt$726.56M$760.47M$775.00M$775.00M$843.75M
Total debt$726.56M$760.47M$775.00M$775.00M$843.75M
Total liabilities$2.56B$2.49B$2.19B$2.09B$2.10B
Shareholders' equity$1.04B$1.55B$1.59B$1.80B$1.68B
Net debt$491.51M$514.09M$498.60M$318.34M$330.30M
Cash flow statement
Operating cash flow$50.38M$129.38M$139.96M$264.47M$312.43M
Capital expenditure$81.44M$104.42M$66.86M$42.34M$48.02M
Free cash flow-$31.05M$24.96M$73.09M$222.13M$264.40M
Investing cash flow-$108.06M-$390.81M-$94.18M-$58.58M-$161.44M
Financing cash flow$28.34M$237.86M-$229.93M-$251.95M-$98.23M
Depreciation & amortization$44.80M$42.40M$40.90M$40.10M$39.40M
Stock-based compensation$18.58M$24.38M$20.14M$27.73M$36.21M
Share buybacks$221,000$52.47M$275.00M$125.00M$0

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.